May 16, 2017 / 11:21 AM / 2 months ago

BRIEF-Xenetic Biosciences reports Q1 loss per share $0.34

1 Min Read

May 16 (Reuters) - Xenetic Biosciences Inc-

* Xenetic Biosciences reports 2017 first quarter financial results and provides business update

* Xenetic Biosciences -on track to commence patient recruitment for lead product candidate xbio-101 for treatment of progestin resistant endometrial cancer

* Xenetic Biosciences Inc qtrly loss per share $0.34 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below